SOURCE: Biophan Technologies, Inc.

February 27, 2008 07:00 ET

Biophan Announces Appointment of Jeanne Lesniak as Advisor for Regulatory and Clinical Affairs for Myotech

PITTSFORD, NY--(Marketwire - February 27, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced the appointment of Jeanne Lesniak as one of two advisors for Regulatory and Clinical Affairs for Myotech, LLC, effective immediately. Myotech is a majority-owned subsidiary of Biophan Technologies, Inc.

For the past 16 years, Ms. Lesniak has served as President and CEO of Lesniak & Associates, a medical device consulting firm focused on business and market development for emerging technologies. In this capacity Ms. Lesniak has acted as an FDA liaison for new medical device product development, clinical research, product approval strategies, and product classifications/designations. She is also experienced in the design and implementation of clinical research studies and investigational plans. Ms. Lesniak is an acting Vice President at several early stage medical device companies.

Previously, Ms. Lesniak has served as Director of Regulatory Affairs and Quality Assurance for Thermo Cardiosystems, Inc. From 1989 to 1991 she was the Director of Corporate Regulatory Affairs at Boston Scientific Corporation. She has occupied numerous consulting roles implementing new product approval strategies and conducting clinical investigations.

Ms. Lesniak received her B.S. in Biomedical Engineering from Boston University.

The Myotech Circulatory Support System (CSS) consists of an external drive unit and flexible polymer cup that slips over the heart and provides the energy that enables the heart to restore normal blood flow. It can be installed in approximately three minutes with a small incision to provide immediate, life-saving support for use in resuscitation and insufficient cardiac output indications. Since it has no contact with circulating blood, the Myotech CSS also has been demonstrated to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:

    Carolyn Hotchkiss
    Biophan Technologies, Inc.
    Communications Manager
    (585) 267-4800
    Email Contact